BIPAP No Backup denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for bipap no backup are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied BiPAP (Without Backup Rate) as Experimental

An experimental or investigational denial for BiPAP without a backup rate is unusual given the device's longstanding use in sleep medicine and respiratory care, but it does occur — typically when the documented diagnosis is outside the most common covered indications, when the billing or diagnosis code does not align with Cigna's published covered criteria, or when Cigna's clinical policy has not yet been updated to reflect current professional society guidance for a particular condition. Identifying exactly which indication or clinical context triggered the experimental classification is the first step in building an appeal.

## Why This Denial Is Appealable

BiPAP devices are covered by Cigna — and by Medicare as a reference standard — for established indications. If the device was prescribed for a condition that Cigna's policy currently lists as experimental, your appeal should present the applicable professional society guidance (such as that from the American Academy of Sleep Medicine or the American Thoracic Society, as relevant to your diagnosis) and your prescriber's explanation of how the prescribed use aligns with accepted clinical practice. Where the society guideline addresses the use, a well-constructed appeal citing its existence and your prescriber's clinical rationale is typically sufficient.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA): File within the deadline on the denial notice. Obtain Cigna's exact coverage policy language to understand which specific use was classified as experimental.
• External review (ACA §2719): After the final internal denial, an IRO reviews whether the experimental classification is consistent with generally accepted medical practice — the standard explicitly requires the IRO to consider current evidence. File within approximately four months of the final internal denial.
• Expedited review: Available with prescriber certification of urgent need.

## Concrete Appeal Steps

1. Request Cigna's coverage policy for BiPAP (positive airway pressure) and identify the specific criterion or indication that was classified as experimental. 2. Confirm the ICD-10 diagnosis code submitted on the claim matches the patient's diagnosis and the indication in the prescriber's order. 3. Ask your prescriber to identify the applicable professional society or clinical practice guideline that addresses use of BiPAP for the patient's diagnosis. 4. Have your prescriber write a letter citing the guideline organization, the basis for the prescription, and why the use is consistent with accepted clinical practice. 5. File the internal appeal in writing with all documentation.

## Documentation to Gather

• Diagnosis documentation: The exact diagnosis (with ICD-10 code) underlying the BiPAP prescription, with supporting clinical notes.
• Diagnostic study results: Sleep study, pulmonary function tests, or other objective data supporting the diagnosis and prescription, as relevant to the underlying condition.
• Prescriber medical-necessity letter: Citing the applicable clinical guideline organization (without specific statistics), explaining the clinical rationale, and attesting that use is consistent with accepted standards of care.
• Coverage policy: Cigna's published policy identifying the experimental classification, so the appeal can address the specific language used.

## Criteria-Mapping Structure

Identify every evidentiary criterion in Cigna's experimental/investigational policy that the reviewer applied. For each criterion, provide: (1) the clinical guideline organization that addresses the use (cited by name and version, not statistics); (2) your prescriber's assessment that the use is within accepted practice; (3) the objective diagnostic data supporting the prescription. A point-by-point response aligned to Cigna's own policy language gives the internal reviewer — and any subsequent IRO reviewer — a clear path to a different determination.